secwatch.observer — SEC 8-K summary
======================================

Issuer:     Climb Bio, Inc. (CLYM)
CIK:        0001768446
Form:       8-K
Filed at:   2026-03-05T23:59:59+00:00
Accession:  0001193125-26-092520
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Climb Bio reports Q4/FY2025 results; cash $160.7M; pipeline trials on track with data in 2026
--------------------------------------------------------------------------------

- Cash, cash equivalents, and marketable securities $160.7M as of Dec 31, 2025; expected runway into 2028.
- FY2025 R&D expense $46.7M vs $14.3M in FY2024; G&A expense $21.2M vs $16.0M.
- Budoprutug SC formulation Phase 1 dosing completed; data expected H1 2026.
- Budoprutug pMN, ITP, SLE trials ongoing; initial efficacy data expected H2 2026.
- CLYM116 Phase 1 healthy volunteer study enrollment ongoing; initial data expected mid-2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1768446/000119312526092520/0001193125-26-092520-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1768446/000119312526092520/clym-20260305.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-092520

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer